Career history of Geoffrey Norman Vaughan
Former positions of Geoffrey Norman Vaughan
| Companies | Position | Start | End |
|---|---|---|---|
| IDT AUSTRALIA LIMITED | Director/Board Member | 2009-08-05 | 2012-06-29 |
| Independent Dir/Board Member | 2011-08-03 | 2012-06-29 | |
Cytopia Ltd.
 Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | Director/Board Member | 2010-03-01 | 2011-07-25 |
| Independent Dir/Board Member | 1998-05-07 | 2011-07-25 | |
| Australia Department of Industry, Tourism & Resources | Corporate Officer/Principal | 2011-02-17 | - |
| Therapeutic Goods Administration | Corporate Officer/Principal | - | - |
Statistics
International
| Australia | 5 |
Operational
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 3 |
| Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| IDT AUSTRALIA LIMITED | Health Technology |
| Private companies | 3 |
|---|---|
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | Health Technology |
| Therapeutic Goods Administration | |
| Australia Department of Industry, Tourism & Resources | Government |
